Captura Biopharma

Executive Summary

Captura Biopharma is a preclinical-stage biopharmaceutical company developing C2E2, an oral small-molecule solution designed to bind and eliminate radioactive heavy metals and radionuclides from the body. Founded in 2021 and headquartered in San Diego, the company addresses a critical gap in medical countermeasures for radiation exposure, particularly in mass casualty scenarios where intravenous treatments are impractical. C2E2 is positioned as a non-invasive, easily deployable therapy for nuclear accidents or incidents, with potential use in both acute and chronic exposure settings. The company is privately held and has not disclosed funding amounts or valuation. As a preclinical entity, Captura faces significant development and regulatory risks, but its technology offers a differentiated approach compared to existing chelators, which often require intravenous administration and have limited tolerability. If successful, C2E2 could become a standard-of-care for radionuclide decorporation, leveraging its oral route for rapid, widespread distribution. The company's near-term focus is on advancing C2E2 through IND-enabling studies and preparing for first-in-human trials.

Upcoming Catalysts (preview)

• Q3 2026IND Submission for C2E240% success
• Q3 2026Preclinical Efficacy Data Publication or Presentation60% success
• Q3 2026Strategic Partnership or Government Grant Announcement30% success